How is Prevalence of Genetic Diseases Driving Carrier Screening Market?
The market is growing due to the rising number of advanced product launched, increasing availability and affordability of tests, and surging prevalence of genetic diseases across the globe. When type is taken into consideration, the market is divided into targeted carrier screening and expanded carrier screening.
Between these two, the expanded carrier screening division held the larger share of the market in 2019, owing to the extensive usage of NGS and other technologies across the globe. In addition to this, the expanded approach allows for the testing of a number of diseases at once. The category is further predicted to register the faster growth during the forecast period. In terms of application, the market is categorized into fragile X syndrome, cystic fibrosis, sickle cell disease, spinal muscular atrophy, and thalassemia.
Out of all these, the cystic fibrosis category accounted for the largest revenue share of the carrier screening market during the historical period (2014–2019). The prevalence of this diseases is rising rapidly in North America and Europe. In addition to this, people are increasingly becoming aware regarding this health issue and are understanding the importance of it being diagnosed early. This is resulting in the rising demand for testing for this disease.
Geographically, North America dominated the carrier screening market in 2019 and is further predicted to account for the major share of the market during the forecast period as well. This is because of high rate of tests for determining whether a person at risk or just a carrier of a genetic disorder. Furthermore, the advance healthcare infrastructure and the presence of large number of established market players is further predicted to drive the regional market in the years to come.
The prevalence of genetic diseases has been rising rapidly, which is resulting in the growth of the carrier screening market. The severity and risk of genetic disease largely depend on ancestors and parent’s carrier status, owing to which, it is important to screen these diseases early. The American College of Obstetricians and Gynecologists recommend pregnant women to get tested for detecting the risk of such diseases early. Because genetic disease account for a high infant mortality rate, parent are becoming highly concerned regarding their children, which is predicted to drive the market.